STEMCELLS*VERY BAD NEWS*!!!!!!!!! ZIEL 1$!!!!!! - 500 Beiträge pro Seite

[51boyauswedding]

Friday March 8, 8:37 am Eastern Time
StemCells to periodically sell up to 15 mln shares
WASHINGTON, March 8 (Reuters) - Biotechnology firm StemCells Inc. (NasdaqNM:STEM - news) filed on Friday with the Securities and Exchange Commission to periodically sell up to 15 million common shares currently worth $40 million.

The Palo Alto, California-based company plans to use the net proceeds for general corporate purposes, including working capital, product development and capital expenditures, it said in the shelf filing.

Under such a filing, a company may sell securities from time to time in one or more separate offerings in amounts, at prices and on terms to be determined at the time of sale.

StemCell shares closed on Thursday at $2.66 on Nasdaq.





RAUS AUS STEMCELLS!!!!!!

BALD 1$!

[Sugar2000]

Ich denke nicht, dass wir 1$ sehen werden! Die Unterstützung bei 2 $ ist super!! Da gehen wir nicht tiefer!
Außerdem wird Stemcells nicht einfach so ein paar Millionen Aktien auf den Markt werfen! Die bringen erst gute News und dann plazieren die nach und nach die Aktien, so das man davon nicht viel mitbekommt!
Meine Meinung bleibt "strong buy" und ich werde bei Kursen von 2EUR weiter einkaufen!!

Gruß
Sugar

[LMeister7]

Hallo,
ich meine, dass zunächst mal die SEC zustimmen muss und dass bei diesem Kurs sich ein derartige Menge nur bei Grossinvestoren plazieren liesse. Das hilft zwar nicht unbedingt dem Kurs aber ich kann mit nicht vorstellen, dass wir vor `nem Ausverkauf stehen. Ich sehe das Ganze als Option für Stem zur Kapitalbeschaffung die z.Zt. bei 13 Mill. USD Cash nicht unbedingt nötig ist. Auf Spekulationen um eine bevorstehende durch News ausgelöste Hype würde ich nicht setzen. In Frage käme auch ein Split. Aber da müssten ja wohl die Aktionäre zustimmen.
Na ja abwarten und Tee trinken.
MfG,
LM7

[foggedi]

yo, yo...

ich denke die aktion mit den 15 mio aktien ist eingepreist und so sehr ging es gar nicht nach unten...
ich habe die gelegenheit zum nachkaufen genutzt...

nachdem am freitag der NBI über 800 pkt geschlossen hat (so gut wie auf tageshoch) könnte es sein, daß STEM erst mal nachholbedarf hat wieder bis auf 3 € hochkommt
(dies ist nur meine einschätzung)

viel erfolg !!!

<<< foggedi >>>

[LMeister7]

"Guten Morgen"
News von Stemcells. Das bedeutet, übern Daumen gepeilt eine Verdreifachung Free-Floats. Entweder ist da tierisch was im Busch oder die spritzen sich ihre auf Grössewahn manipulierten Stammzellen selber:
________________________________________________________
StemCells Seeks To Up Auth Common Shares To 75 Million From 45 Million

WASHINGTON -(Dow Jones)- StemCells Inc. (STEM) plans to increase to 75 million from 45 million the number of common shares it`s authorized to issue, according to a preliminary proxy filed Monday with the Securities and Exchange Commission.
The biomedical company`s shareholders can vote on the proposed increase at their annual meeting May 2 in Palo Alto, Calif.
StemCells said in the proxy that it has about 24.2 million shares outstanding and another 15.7 million reserved for issuance through options and warrants, equity incentives or conversion of preferred stock. The company could use the additional shares for stock splits, license agreements, acquisitions or for raising more capital, the proxy said.
-Christopher Scinta; Dow Jones Newswires; 202-628-7699; chris.scinta@ dowjones.com
(This story was originally published by Dow Jones Newswires)
__________________________________________________________
Hier noch der Link:http://www.nasdaq.com/asp/quotes_news.asp?source=US&symbol=M…
MfG,
LM7

[IngoBerndt]

Kann das mal jemand ins deutsche übersetzen.Danke

[sohu]

Ich kaufe erst bei 1$!

[sohu]

bald sehen wir die 1$

[sohu]

bald sehen wir die 1$

[suxxx]

stem ist am ende!!!

bald delisting unter 1$!!!!!!

[LMeister7]

@ suxxx
Hallo,
hoffentlich, wäre `ne günstige Gelegenheit zum Nachlegen. Der Dollar ist auch etwas günstiger geworden. Liquiditätsprobleme gibt`s z.Zt. auch nicht und "good News" gab´s ewig nicht von STEM. Die nächste Hype kommt bestimmt und da ist es besser man hat schon welche und muss nicht aufspringen. Soll schon böse Verletzungen gegeben haben. Merke: Wer zu spät kommt, den.....!
In diesem Sinne,
LM7

[SparDeinGeldBua]

stem ist ja äusserst starkt in diesem schwachen umfeld. kennt jemand den grund, warum schon seit mehreren tagen langsam aber stetig gekauft wird?

[v3a]

anscheinen weiß keine was.
viele grüße v3a

[SparDeinGeldBua]

stem laufen noch immer wie eine glocke. entweder die zahlen werden gut (muss doch mal schauen, wann die kommen) oder sonstige gute news. wunderschöner uptrend. sollten noch ein paar % drin sein. kaufe nach, wenn sie durch die 2$ marke gehen.

[IngoBerndt]

Ja schau mal wann die Zahlen kommen und sags mir bitte

[SparDeinGeldBua]

zahlen kommen anscheinend am 8. august 2002. schätze, dass stem bis dann noch gut 20% machen. kaufe heute zu 2 euro nach.

[DOXA DRAMA]

StemCells, Inc. Announces Second Quarter 2002 Financial Results

PALO ALTO, Calif., Aug. 2 /PRNewswire-FirstCall/ --
StemCells, Inc. (NASDAQ:STEM) today reported financial results for the second
quarter ended June 30, 2002. StemCells` net loss was $3.1 million, or $0.13
per diluted share, for the second quarter of 2002, compared to a net income of
$1.6 million, or $0.07 per diluted share, for the same period in 2001. Cash
and cash equivalents were $7.8 million at June 30, 2002, compared to $9.4
million at June 30, 2001.
The change in net results from 2001 to 2002 was primarily attributable to
the effect of a realized gain of $5.2 million from the sale of
available-for-sale securities in the second quarter of 2001 and costs related
to an increase in personnel in 2002.
StemCells, Inc. is a biotechnology company focused on the discovery,
development and commercialization of stem cell-based therapies to treat
diseases of the central nervous system, liver and pancreas. The Company`s stem
cell programs seek to repair or repopulate neural or other tissue that has
been damaged or lost as a result of disease or injury.


StemCells, Inc.
Condensed Consolidated Statement of Operations
(Unaudited)

Three Months Ended Six Months Ended
(in thousands, except June 30, June 30,
share and per
share amounts) 2002 2001 2002 2001


Revenue from grants/
licensing agreements/
assignment of
technology rights $125 $300 $236 $400


Operating expenses
Research &
Development 2,115 2,859 3,651 4,503

General &
administrative 1,051 1,100 2,391 2,097


Total operating
expenses 3,166 3,959 6,042 6,600


Loss from operations (3,041) (3,659) (5,806) (6,200)


Other income (expense) (17) 5,254 (62) 8,063


Net income (loss)
per share $(3,058) $ 1,595 $(5,868) $ 1,863


Earnings per share
before dividends to
preferred shareholders
Basic earnings per share

Net income (loss)
per share (0.13) $0.07 $(0.24) $0.09

Shares -- basic net
income (loss)
per share 24,354,705 21,511,171 24,288,198 21,251,591

Diluted earnings per
share

Net income (loss)
per share $(0.13) $0.07 $(0.24) $0.08

Shares -- diluted
net income (loss)
per share 24,354,705 23,264,606 24,288,198 23,005,026


StemCells. Inc.
Consolidated Balance Sheets

June December
2002 2001
(in thousands) (Unaudited) (a)
Current assets
Cash & cash equivalents 7,782 13,697

Receivables 326 54

Other current assets 126 362

Total current assets 8,234 14,113


Property held for sale 3,204 3,204

Property, plant & equipment net 1,182 1,219

Other assets net 2,636 2,267

Total Assets 15,256 20,803


Liabilities and stockholders equity
Current liabilities 1,407 1,367

Non-current liabilities 4,146 3,566

Convertible preferred Stock 2,661 2,663

Stockholders`equity 7,042 13,207

Total liability and stockholders` equity 15,256 20,803


(a) Derived from audited financial statements
included in StemCells` annual report on
form 10K/A, filed with the SEC

Apart from statements of historical facts, the text of this press release
constitutes forward-looking statements regarding, among other things, the
future business operations of StemCells, Inc. ("the Company"). The Company`s
actual results may vary materially from those contemplated in the
forward-looking statements due to risks and uncertainties to which the Company
is subject, including uncertainties regarding the Company`s ability to obtain
the capital resources needed to conduct the research, pre-clinical development
and clinical trials necessary for regulatory approvals; the fact that the
Company`s stem cell technology is at the pre-clinical stage and has not yet
led to the development of any proposed product; the uncertainty whether the
Company will achieve revenues from product sales or become profitable; and
other factors that are described in Exhibit 99 to the Company`s Annual Report
on Form 10-K entitled "Cautionary Factors Relevant to Forward-Looking
Statements."

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X37778940

SOURCE StemCells, Inc.
-0- 08/02/2002
/CONTACT: Martin McGlynn, President and CEO of StemCells, Inc.,
[phone], ext. 108; or investors - Jonathan Fassberg, 212-477-9007,
ext. 16, or media: Brad Miles, 212-477-9007, ext. 17, both of Trout Group-BMC
Comm. Group, for StemCells, Inc./

- - - - -

[SparDeinGeldBua]

hatte erst am 8. mit zahlen gerechnet. ist irgendwie nichts besonderes. keine fantasie. überlege direkt wieder auszusteigen. mit der meldung ist schnell wieder 1,5 bei dem markt drin.

[thebull 2]

Stem cell work `a mess`
Fund shortage, disputes bedevil crucial research
By Paul Elias
ASSOCIATED PRESS
SAN FRANCISCO — A year after U.S. George
W. President Bush restricted federal funding for human embryonic stem cell
research to a select number of existing cell lines, leading scientists say the field
is hampered by political, financial and scientific chaos.

An overwhelming majority of the stem cells the Bush administration approved
are in poor condition and useless for research, they complain.

What`s more, a lack of funds, a charged political climate and intellectual
property disputes are slowing progress in a field scientists believe is vital to
more effectively treating — and even curing — a wide range of diseases.

"It really is a mess," said Stanford University Medical School professor Paul
Berg, a Nobel laureate and one of the first high-profile critics of the
administration`s policy. "There are so many things that have to happen to make
this work.``

Chief among the complaints is the relative lack of money devoted to such
research — most of it coming from small, private foundations backed by ailing
actors — the Christopher Reeve Paralysis Foundation and the Michael J. Fox
Foundation for Parkinson`s Research — along with the Juvenile Diabetes
Research Foundation.

Those three foundations have committed a combined $6 million (U.S.) to
human embryonic stem cell researchers, compared with just $3.5 million by
the National Institutes of Health.

The NIH said it can`t be blamed entirely for the funding drought. Only in
November was it ready to dole out stem cell grants and researchers themselves
have been slow to apply, said Wendy Baldwin, who helps manage the NIH`s
stem cell program.

"We are here and ready to fund," she said.

Even large foundations such as the American Heart Association and the
American Cancer Society have shied away from this political hot potato and
are explicitly declining to fund it.

Dr. Robert Bonow, president of the Heart Association, said debate continues
inside the organization among doctors, researchers and patients. Bonow said
the possibility of losing donors opposed to such research is a concern. "It is a
controversial area. It certainly is an issue.``

Scientists hope to some day manipulate stem cells to grow into all kinds of
adult cells. But many anti-abortion activists equate the science with murder
because 5-day-old embryos must be destroyed to harvest embryonic stem
cells.

Pressure from political conservatives preceded the decision Bush announced
last Aug. 9 that the government would only fund research of existing stem cell
lines.

A new private funding source that could more than double available stem cell
research money emerged in a $5 million challenge grant announced Thursday
by Intel Corp. chairman Andy Grove. He`s giving up to $5 million to the
University of California, San Francisco.

But researchers have long argued that federal support is necessary to nurture
nascent fields into useful science. Companies are reluctant to invest in such
research because the payoffs are far from guaranteed — and years off.

"Very few breakthroughs have come from the business sector,`` Berg said.
"They come from the academic community, which relies on federal funds.``

Indeed, the one U.S. company heavily invested in stem cells — Geron Corp.
— is struggling. In June, the Menlo Park-based company laid off 43
employees, 30 per cent of its workforce, and its stock is trading around $4 a
share, near its 52-week low.

[LMeister7]

@ thebull2
Hallo,
das prekäre ist, dass auch die adulte Forschung in der Luft hängt. In diese sollten ursprünglich 200 Mill.USD fliessen. Bisher keine Spur. Angesichts des Rüstungsbudgets eine armselige Summe! Von wo hast Du(Sie?) den Artikel bzw. wie alt ist er? Hast Du `ne Ahnung wann das Thema im Senat bzw. im Kongress wieder auf der Tagesordnung ist? Ne kleine Rally zwischendurch wär ja nicht schlecht. Von Stemcells selbst kommt ja seit Monaten nichts Brauchbares. Cash reicht bei gleichbleibenden Kosten
noch max. 3 Quartale. Würde mich nicht wundern, wenn sich der Kurs der Cashrate nähert.

MfG,
LM7

[51boyauswedding]

mein kursziel wurde schon längst erreicht!


ich hatte gewarnt das stem abstürzen wird!!!


mein neues kursziel=pleite!

stem vernichtet zuviel geld,und hat nur noch wenig cash!

es ist aus